Humanigen Inc (HGEN):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Humanigen Inc (HGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8001)・商品コード:DATA904C8001
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:39
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Humanigen Inc (Humanigen), formerly KaloBios Pharmaceuticals Inc is a biopharmaceutical company that develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company provides Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF) recombinant monoclonal antibodies, used for the treatment of solid tumors and their micro environment; and certain hematologic malignancies such as chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. It has developed the recombinant monoclonal antibodies using its proprietary drug discovery technology called Humaneered. Humanigen also provides data on on pharmacokinetics and pharmacodynamics including correlative biomarkers and mutational analysis for conducting studies in and juvenile myelomonocytic leukemia. Humanigen is headquartered in Brisbane, California, the US.

Humanigen Inc (HGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Humanigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Humanigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Humanigen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
KaloBios Pharma Acquires Benznidazole Program from Savant Neglected Diseases 11
Venture Financing 12
KaloBios Pharma Raises USD12.2 Million in Venture Financing 12
Kalobios Pharma Raises Additional US$3 Million In Series E Financing 13
Partnerships 14
Humanigen Enters into Research Agreement with MD Anderson Cancer Center 14
Equity Offering 15
Humanigen Plans to Raise up to USD15 Million in Private Placement of Shares 15
KaloBios Pharma Plans to Raise Funds through Public Offering of Shares 16
KaloBios Pharma to Raise Funds through Private Placement of Shares, upon Exercise of Warrant 17
KaloBios Pharma Raises USD8.8 Million in Private Placement of Shares 18
KaloBios Pharma Completes Public Offering Of Shares For US$34.5 Million 19
KaloBios Pharma Completes IPO For US$70 Million 21
Acquisition 24
Martin Shkreli Led Consortium Acquires 70% Stake in KaloBios Pharma 24
Humanigen Inc – Key Competitors 25
Humanigen Inc – Key Employees 26
Humanigen Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Mar 12, 2018: Humanigen Appoints Robert Savage to Board of Directors 28
Feb 07, 2018: Humanigen Names Rainer Boehm As Board Director 29
Aug 28, 2017: Humanigen Appoints Chief Financial Officer 30
Product News 31
04/06/2017: Benznidazole on Track in Progress to IND and NDA Submissions 31
Product Approvals 32
Jul 11, 2017: KaloBios Receives Orphan Drug Designation for Benznidazole in the Treatment of Chagas Disease 32
Jun 27, 2017: Benznidazole IND for Chagas Disease Receives Clearance by FDA 33
May 30, 2017: KaloBios Submits IND Application for Benznidazole to FDA 34
Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole 35
Clinical Trials 36
Aug 08, 2017: Humanigen Announces Completion of Benznidazole Bioavailability Study 36
Other Significant Developments 37
Aug 07, 2017: Humanigen is Effective Today 37
Jul 27, 2017: KaloBios To Change Company Name To Humanigen 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Humanigen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Humanigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Humanigen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Humanigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
KaloBios Pharma Acquires Benznidazole Program from Savant Neglected Diseases 11
KaloBios Pharma Raises USD12.2 Million in Venture Financing 12
Kalobios Pharma Raises Additional US$3 Million In Series E Financing 13
Humanigen Enters into Research Agreement with MD Anderson Cancer Center 14
Humanigen Plans to Raise up to USD15 Million in Private Placement of Shares 15
KaloBios Pharma Plans to Raise Funds through Public Offering of Shares 16
KaloBios Pharma to Raise Funds through Private Placement of Shares, upon Exercise of Warrant 17
KaloBios Pharma Raises USD8.8 Million in Private Placement of Shares 18
KaloBios Pharma Completes Public Offering Of Shares For US$34.5 Million 19
KaloBios Pharma Completes IPO For US$70 Million 21
Martin Shkreli Led Consortium Acquires 70% Stake in KaloBios Pharma 24
Humanigen Inc, Key Competitors 25
Humanigen Inc, Key Employees 26
Humanigen Inc, Subsidiaries 27

List of Figures
Humanigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Humanigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Humanigen Inc (HGEN):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8001)販売に関する免責事項を必ずご確認ください。
★調査レポート[Humanigen Inc (HGEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆